Hamada Akinobu 濱田哲暢

… Alternative Names

濱田哲暢ハマダアキノブ

HAMADA Akinobu 濱田哲暢

Less

Researcher Number	00322313
Other IDs
Affiliation (Current)	2025: 国立研究開発法人国立がん研究センター, 研究所, 分野長
Affiliation (based on the past Project Information) *help	2021: 国立研究開発法人国立がん研究センター, 研究所, 分野長 2015: 国立研究開発法人国立がん研究センター, その他部局等, 分野長 2015: 国立研究開発法人国立がん研究センター, 先端医療開発センター, 分野長 2014: 独立行政法人国立がん研究センター, 早期探索臨床研究センター, ユニット長 2013: 独立行政法人国立がん研究センター, 研究所, 部門長 … More 2007 – 2011: Kumamoto University, 医学部附属病院, 准教授 2008: Kumamoto University, 医学部・附属病院, 准教授 2002 – 2004: 熊本大学, 医学部附属病院, 講師 Less
Review Section/Research Field	Principal Investigator Medical pharmacy Except Principal Investigator Medium-sized Section 50:Oncology and related fields / Respiratory organ internal medicine / 応用薬理学・医療系薬学 / Medical pharmacy / Applied pharmacology
Keywords	Principal Investigator 薬理遺伝学 / オーダーメード医療 / LC/MS/MS / 薬理遺伝学的解析 / 臨床薬理 / エリブリン / クリゾチニブ / ABCB1 / 個別化医療 / 薬物動態 … More / 薬剤反応性 / 癌 / 分子標的薬 / 抗悪性腫瘍薬 / 個別投与設計 … More Except Principal Investigator 薬物トランスポータ / UGT / CYP / PD / PK / TDM / シスプラチン / インドキシル硫酸 / 尿毒症物質 / 薬物排泄 / 腎障害 / 腎尿細管 / 薬剤性腎障害 / 急性腎障害 / 抗がん剤 / C/EBPα / 分化誘導 / Docetaxel / Irinotecan Hydrochloride / Carboplatin / Paclitaxel / バクリタキセル / ドセタキセル / 塩酸イリノテカン / カルボプラチン / パクリタキセル / Renal failure / Dosage regimen / Nephrotoxicity / Renal tubular dysfunction / Renal excretion / Drug transporter / 遺伝子発現 / カチオン性薬物 / アニオン性薬物 / 投与設計 / 有機カチオン / 有機アニオン / 尿細管分泌 / 腎不全 / 薬物投与設計 / 尿細管障害 / 腎排泄 / 虚血 / 酸化ストレス / 腎虚血 / 慢性腎不全 / 抗癌薬 Less

Development of a novel cell differentiation cancer therapy
- Principal Investigator
  
  小林進
- Project Period (FY)
  2021 – 2024
- Research Category
  
  Fund for the Promotion of Joint International Research (Fostering Joint International Research (B))
- Review Section
  
  Medium-sized Section 50:Oncology and related fields
- Research Institution
  National Cancer Center Japan
Personalized cancer chemotherapy: efficacy and safety based on pharmacokinetics and pharmacogeneticsPrincipal Investigator
- Principal Investigator
  
  Hamada Akinobu
- Project Period (FY)
  2013 – 2015
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Medical pharmacy
- Research Institution
  National Cancer Center Japan
Novel strategy for development of suppressive drugs for kidney disease based on inhibition of metabolic production of uremic toxins
- Principal Investigator
  
  SAITO Hideyuki
- Project Period (FY)
  2009 – 2011
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Research Field
  
  Medical pharmacy
- Research Institution
  Kumamoto University
Development of personalized medicine for cancer chemotherapy according to a variety of sensitivity and pharmacokineticsPrincipal Investigator
- Principal Investigator
  
  HAMADA Akinobu
- Project Period (FY)
  2009 – 2011
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Medical pharmacy
- Research Institution
  Kumamoto University
Development of an individualized therapy for establishing the optimal dosage by analysis of pharmacological genePrincipal Investigator
- Principal Investigator
  
  HAMADA Akinobu
- Project Period (FY)
  2007 – 2008
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Medical pharmacy
- Research Institution
  Kumamoto University
Strategy for protection of kidney injury based on functioal relation betwee renal specific stress response mechanisms and xenobiotic detoxication systems
- Principal Investigator
  
  SAITO Hideyuki
- Project Period (FY)
  2005 – 2008
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Research Field
  
  Applied pharmacology
- Research Institution
  Kumamoto University
Molecular Biological Studies on Relationships between Changes in Renal Tubular Transporter Gene Expressions and Deterioration of Drug Excretory Functions in Renal Diseases
- Principal Investigator
  
  SAITO Hideyuki
- Project Period (FY)
  2002 – 2004
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Research Field
  
  応用薬理学・医療系薬学
- Research Institution
  Kumamoto University
The prediction of adverse effect and determination of the maximum tolerated dose in chemotherapy of lung cancer based on clinical and molecular pharmacology
- Principal Investigator
  
  KONDO Keiichi
- Project Period (FY)
  2002 – 2003
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  HIROSHIMA UNIVERSITY

All 2015 2012 2011 2010 2009 2008 2007 2005 2003

All Journal Article Presentation Patent

[Journal Article] Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small cell lung cancer2012
- Author(s)
  Hamada A
- Journal Title
  
  Pharmacogenomics
  
  Volume: (印刷中)
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21590167
[Journal Article] Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient2012
- Author(s)
  Tsubata Y, Hamada A, Sutani A, Isobe T
- Journal Title
  
  Journal of Cancer Research and Therapeutics
  
  Volume: 8 Pages: 154-156
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21590167
[Journal Article] Effects of genetic variants in SLC22A2 organic cation transporter2and SLC47A1 multidrug and toxin extrusion1transporter on cisplatin-induced adverse events2012
- Author(s)
  Iwata K, Aizawa K, Kamitsu S, Ji ngami S, Fukunaga E, Yoshida M, Yoshimura M, Hamada A, Saito H
- Journal Title
  
  Clin Exp Nephrol
  
  Volume: (accepted)
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21590167
[Journal Article] Effects of Genetic Variants in SLC22A2 Organic Cation Transporter 2 and SLC47A1 Multidrug and Toxin Extrusion 1 Transporter on Cisplatin-induced Adverse Events2012
- Author(s)
  Iwata K, Aizawa K, Kamitsu S, Jingami S, Fukunaga E, Yoshida M, Yoshimura M, Hamada A, Saito H
- Journal Title
  
  Clin Exp Nephrol
  
  Volume: (in press)
- NAID
  10031145916
- Data Source
  KAKENHI-PROJECT-21390048
[Journal Article] Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis2012
- Author(s)
  Kato T, Hamada A, Mori S, Saito H
- Journal Title
  
  Drug Metab Pharmacokinet
  
  Volume: (in press)
- NAID
  130004463237
- Data Source
  KAKENHI-PROJECT-21390048
[Journal Article] Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small cell lung cancer2012
- Author(s)
  Hamada A, Sasaki J, Saeki S, Iwamoto N, Inaba M, Ushijima S, Urata M, Kishi H, Fujii S, Semba H, Kashiwabara K, Tsubata Y, Kai Y, Isobe T, Kourogi H, Saito H
- Journal Title
  
  Pharmacogenomics
  
  Volume: 13 Pages: 615-624
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21590167
[Journal Article] The relationship between treatment time of gemcitabine and development of hematologic toxicity in cancer patients2011
- Author(s)
  Iwata K, Aizawa K, Sakai S, Jingami S, Fukunaga E, Yoshida M, Hamada A, Saito H
- Journal Title
  
  Biol Pharm Bull
  
  Volume: 34(11) Pages: 1765-1768
- NAID
  130001252863
- Data Source
  KAKENHI-PROJECT-21390048
[Journal Article] High-performance liquid chromatographic assay for the determination of nilotinib in human plasma2011
- Author(s)
  Yuki M, Yamakawa Y, Uchida T, Nambu T, Kawaguchi T, Hamada A, Saito H
- Journal Title
  
  Biol Pharm Bull
  
  Volume: 34(7) Pages: 1126-1128
- NAID
  130000738108
- Data Source
  KAKENHI-PROJECT-21390048
[Journal Article] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia2011
- Author(s)
  Yamakawa Y, Hamada A, Nakashima R, Yuki M, Hirayama C, Kawaguchi T, Saito H
- Journal Title
  
  Ther Drug Monit
  
  Volume: 33 Pages: 244-250
- NAID
  120005952466
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21590167
[Journal Article] Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia2011
- Author(s)
  Nambu T, Hamada A, Nakashima R, Yuki M, Kawaguchi T, Mitsuya H, Saito H
- Journal Title
  
  Biol Pharm Bull
  
  Volume: 34(1) Pages: 114-119
- NAID
  130000402273
- Data Source
  KAKENHI-PROJECT-21390048
[Journal Article] エルロチニブの薬物動態ならびに有害事象およぼすABCトランスポータ遺伝子多型の影響2011
- Author(s)
  濱田哲暢
- Journal Title
  
  腫瘍内科
  
  Volume: 6 Pages: 35-44
- Data Source
  KAKENHI-PROJECT-21590167
[Journal Article] Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia2011
- Author(s)
  Nambu T, Hamada A, Nakashima R, Yuki M, Kawaguchi T, Mitsuya H, Saito H
- Journal Title
  
  Biol Pharm Bull
  
  Volume: 34 Pages: 114-119
- NAID
  130000402273
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21590167
[Journal Article] Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia2011
- Author(s)
  Yamakawa Y, Hamada A, Shuto T, Yuki M, Uchida T, Kai H, Kawaguchi T, Saito H
- Journal Title
  
  Clin Pharmacol Ther
  
  Volume: 90(1) Pages: 157-163
- NAID
  120005952465
- URL
  http://hdl.handle.net/2298/23261
- Data Source
  KAKENHI-PROJECT-21390048
[Journal Article] High-performance liquid chromatographic assay for the determination of nilotinib in human plasma2011
- Author(s)
  Yuki M, Yamakawa Y, Uchida T, Nambu T, Kawaguchi T, Hamada A, Saito H
- Journal Title
  
  Biol Pharm Bull
  
  Volume: 34 Pages: 1126-1128
- NAID
  130000738108
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21590167
[Journal Article] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia2011
- Author(s)
  Yamakawa Y, Hamada A, Nakashima R, Yuki M, Hirayama C, Kawaguchi T, Saito H
- Journal Title
  
  Ther Drug Monit
  
  Volume: 33(2) Pages: 244-250
- NAID
  120005952466
- Data Source
  KAKENHI-PROJECT-21390048
[Journal Article] Erlotinib efficacy and cerebrospinal fluid concentration in lung adenocarcinoma patients developing leptomeningeal metastases during gefitinib therapy2011
- Author(s)
  Masuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N
- Journal Title
  
  Cancer Chemother Pharmacol
  
  Volume: 67 Pages: 1465-1469
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21590167
[Journal Article] Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia2011
- Author(s)
  Yamakawa Y, Hamada A, Shuto T, Yuki M, Uchida T, Kai H, Kawaguchi T, Saito H
- Journal Title
  
  Clin Pharmacol Ther
  
  Volume: 90 Pages: 157-163
- NAID
  120005952465
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21590167
[Journal Article] Alleviation of cisplatin-induced acute kidney injury using phytochemical polyphenols is accompanied by reduced accumulation of indoxyl sulfate in rats2011
- Author(s)
  Kusumoto M, Kamobayashi H, Sato D, Komori M, Yoshimura M, Hamada A, Kohda Y, Tomita K, Saito H
- Journal Title
  
  Clin Exp Nephrol
  
  Volume: 15(6) Pages: 820-830
- NAID
  10030341588
- Data Source
  KAKENHI-PROJECT-21390048
[Journal Article] The relationship between treatment time of gemicitabine and development of hematologic toxicity in cancer patients2011
- Author(s)
  Iwata K, Aizawa K, Sakai S, Jingami S, Fukunaga E, Yoshida M, Hamada A, Saito H
- Journal Title
  
  Biol Pharm Bull
  
  Volume: 34 Pages: 1765-1768
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21590167
[Journal Article] Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer2010
- Author(s)
  Shimokata T, Ando Y, Yasuda Y, Hamada A, Kawada K, Saito H, Matsuo S, Kondo M, Imaizumi K, Hasegawa Y
- Journal Title
  
  Cancer Sci
  
  Volume: 101 Pages: 2601-2605
- NAID
  10027834680
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21590167
[Journal Article] Serum concentrations of erlotinib at a dose of25mg daily2010
- Author(s)
  Costa DB, Kobayashi S, Yeo WL, Hamada A
- Journal Title
  
  J Thorac Oncol
  
  Volume: 5 Pages: 1311-1312
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21590167
[Journal Article] Contribution of BCR-ABL-independent Activation of ERK1/2 to Acquired Imatinib Resistance in K562Chronic Myeloid Leukemia Cells2010
- Author(s)
  Nambu T, Araki N, Nakagawa A, Kuniyasu A, Kawaguchi T, Hamada A, Saito H
- Journal Title
  
  Cancer Sci
  
  Volume: 10 Pages: 137-142
- NAID
  10027199844
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21590167
[Journal Article] Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats2010
- Author(s)
  Maeda Y, Hamada A, Sanematsu E, Sasaki JI, Yokoo K, Hira A, Saito H
- Journal Title
  
  Cancer Chemother Pharmacol
  
  Volume: 65(5) Pages: 953-959
- NAID
  120002469644
- Data Source
  KAKENHI-PROJECT-21390048
[Journal Article] Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells2010
- Author(s)
  Nambu T, Araki N, Nakagawa A, Kuniyasu A, Kawaguchi T, Hamada A, Saito H
- Journal Title
  
  Cancer Sci
  
  Volume: 101(1) Pages: 137-142
- NAID
  10027199844
- Data Source
  KAKENHI-PROJECT-21390048
[Journal Article] P-Glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines2009
- Author(s)
  Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, Tanoue N, Hamada A, Saito H
- Journal Title
  
  Biol Pharm Bull
  
  Volume: 32 Pages: 1588-1593
- NAID
  130000117288
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21590167
[Journal Article] Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer2009
- Author(s)
  Yokoo K, Hamada A, Tazoe K, Sasaki Y, Saito H.
- Journal Title
  
  Ther Drug Monit (in press)
- NAID
  120002469601
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17390158
[Journal Article] Relationship between an effective dose of imatinib2009
- Author(s)
  Kawaguchi T, Hamada A, Hirayama C, Nakashima R, Nambu T, Yamakawa Y, Watanabe H, Horikawa H, Mitsuya H, Saito H
- Journal Title
  
  body surface area, and trough drug levels in patients with chronic myeloid leukemia (in press)
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19590149
[Journal Article] P-Glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines2009
- Author(s)
  Fujimoto H, Hicuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, Tanoue N, Hamada A, Saito H
- Journal Title
  
  Biol Pharm Bull
  
  Volume: 32(9) Pages: 1588-1593
- NAID
  130000117288
- Data Source
  KAKENHI-PROJECT-21390048
[Journal Article] Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats2009
- Author(s)
  Yokoo K, Murakami R, Matsuzaki T, Yoshitome K, Hamada A, Saito H
- Journal Title
  
  Clin Exp Nephrol
  
  Volume: 13(6) Pages: 578-584
- NAID
  10027227458
- URL
  http://hdl.handle.net/2298/15589
- Data Source
  KAKENHI-PROJECT-21390048
[Journal Article] Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia2009
- Author(s)
  K awaguchi T, Hamada A, Hirayama C, Nakashima R, Nambu T, Yamakawa Y, Watanabe H, Horikawa H, Mitsuya H, Saito H
- Journal Title
  
  Int J Hematol
  
  Volume: 89 Pages: 642-8
- NAID
  10025161955
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21590167
[Journal Article] Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells2009
- Author(s)
  Hirayama C, Watanabe H, Nakashima R, Nanbu T, Hamada A, Kuniyasu A, Nakayama H, Kawaguchi T, Saito H.
- Journal Title
  
  Pharm Res. 25
  
  Pages: 827-835
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17390158
[Journal Article] Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats2009
- Author(s)
  Maeda Y, Hamada A, Sanematsu E, Sasaki J, Yokoo K, Hira A, Saito H
- Journal Title
  
  Can cer Chemother Pharmacol
  
  Volume: 65 Pages: 653-659
- NAID
  120002469644
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21590167
[Journal Article] Effects of oral administered S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer.2009
- Author(s)
  Yokoo K, Hamada A, Tazoe K, Sasaki Y, Saito H
- Journal Title
  
  Ther Drug Monit (in press)
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19590149
[Journal Article] Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells2008
- Author(s)
  Hira A, Watanabe H, Maeda Y, Yokoo K, Sanematsu E, Fujii J, Sasaki JI, Hamada A, Saito H.
- Journal Title
  
  Biochem Pharmacol 75
  
  Pages: 973-980
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17390158
[Journal Article] Altered pharmacokinetics of cationic drugs caused by down-regulation of renal rOCT2 (Slc22a2)and rMATE1 (Slc47a1)in ischemia/reperfusioninduced acute kidney injury2008
- Author(s)
  Matsuzaki T, Morisaki T, Sugimoto W, Yokoo K, Sato D, Nonoguchi H, Tomita K, Terada T, Inui K, Hamada A, Saito H.
- Journal Title
  
  Drug Metab Dispos 36
  
  Pages: 649-654
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17390158
[Journal Article] Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells2008
- Author(s)
  Hirayama C, Watanabe H, Nakashima R, Nanbu T, Hamada A, Kuniyasu A, Nakayama H, Kawaguchi T, Saito H
- Journal Title
  
  Pharm Res 25
  
  Pages: 827-835
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19590149
[Journal Article] Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells2008
- Author(s)
  Hira A, Watanabe H, Maeda Y, Yokoo K, Sanematsu E, Fujii J, Sasaki J, Hamada A, Saito H
- Journal Title
  
  Biochem Pharmacol 75
  
  Pages: 973-980
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19590149
[Journal Article] Regulation of renal organic ion transporters in cisplatin-induced acute kidney injury and uremia in rats2008
- Author(s)
  Morisaki T, Matsuzaki T, Yokoo K, Kusumoto M, Iwata K, Hamada A, Saito H
- Journal Title
  
  Pharm Res. 25
  
  Pages: 2526-2533
- NAID
  120002469602
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17390158
[Journal Article] Downregulation of organic anion transporters in rat kidney under ischemia/reperfusion-induced acute renal failure2007
- Author(s)
  Matsuzaki T, Watanabe H, Yoshitome K, Morisaki T, Hamada A, Nonoguchi H, Kohda Y, Tomita K, Inui K, Saito H
- Journal Title
  
  Kidney Int. 71
  
  Pages: 539-547
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17390158
[Journal Article] Involvement of indoxyl sulfate in renal and central nervous system toxicities during cisplatin-induced acute renal failure2007
- Author(s)
  Iwata K, Matsuzaki T, Watanabe H, Morisaki T, Ohmura T, Hamada A, SaitoH.
- Journal Title
  
  Pharm Res. 24
  
  Pages: 662-671
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17390158
[Journal Article] Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient.2005
- Author(s)
  Hamada A, et al.
- Journal Title
  
  Ther Drug Monit. 27・4
  
  Pages: 536-538
- Data Source
  KAKENHI-PROJECT-17390158
[Journal Article] Pharmacokinetic changes of Irinotecan by intestinal alkalization in advanced colorectal cancer patient.2005
- Author(s)
  Hamada A.
- Journal Title
  
  Therap.Drug Monit. (in press)
- Description
  「研究成果報告書概要(欧文)」より
- Data Source
  KAKENHI-PROJECT-14370781
[Journal Article] Interaction of imatinib mesilate with human P-glycoprotein.2003
- Author(s)
  Hamada, A.
- Journal Title
  
  J.Pharmacol.Exp.Ther. 307(2)
  
  Pages: 824-828
- Description
  「研究成果報告書概要(欧文)」より
- Data Source
  KAKENHI-PROJECT-14370781
[Patent] インドキシル硫酸の産生の阻害剤のスクリーニング方法、インドキシル硫酸代謝産生阻害剤、及び腎障害軽減剤2010
- Inventor(s)
  齋藤秀之、濱田哲暢
- Industrial Property Rights Holder
  国立大学法人熊本大学
- Industrial Property Number
  2010-234185
- Filing Date
  2010-10-19
- Data Source
  KAKENHI-PROJECT-21390048
[Patent] インドキシル硫酸の産生の阻害剤のスクリーニング方法、インドキシル硫酸代謝産生阻害剤、及び腎障害軽減剤2010
- Inventor(s)
  齋藤秀之, 濱田哲暢
- Industrial Property Rights Holder
  熊本大学
- Industrial Property Number
  2010-234185
- Filing Date
  2010-10-19
- Data Source
  KAKENHI-PROJECT-21390048
[Patent] エルロチニブの副作用又は薬効を判定する方法2009
- Inventor(s)
  濱田哲暢、佐々木治一郎、齋藤秀之、興梠博次
- Industrial Property Rights Holder
  国立大学法人熊本大学
- Industrial Property Number
  2009-116385
- Filing Date
  2009-05-13
- Data Source
  KAKENHI-PROJECT-19590149
[Patent] エルロチニブの副作用又は薬効を判定する方法2009
- Inventor(s)
  濱田哲暢
- Industrial Property Rights Holder
  熊本大学
- Industrial Property Number
  2009-116385
- Filing Date
  2009-05-13
- Data Source
  KAKENHI-PROJECT-21590167
[Patent] インドキシル硫酸の産生の阻害剤のスクリーニング方法2009
- Inventor(s)
  齋藤秀之, 濱田哲暢
- Industrial Property Rights Holder
  熊本大学
- Industrial Property Number
  2009-240062
- Filing Date
  2009-10-19
- Data Source
  KAKENHI-PROJECT-21390048
[Patent] エルロチニブの副作用又は薬効を判定する方法2009
- Inventor(s)
  濱田哲暢、佐々木治一郎、齋藤秀之、興梠博次
- Industrial Property Rights Holder
  国立大学法人熊本大学
- Industrial Property Number
  2009-116385
- Filing Date
  2009-05-31
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] これからのPK/PD研究の方向性を探る2015
- Author(s)
  濱田哲暢
- Organizer
  日本臨床薬理学会
- Place of Presentation
  東京
- Year and Date
  2015-12-09
- Invited
- Data Source
  KAKENHI-PROJECT-25460202
[Presentation] 副作用とトランスポータ親和性を指標とし抗がん剤個別化治療戦略2011
- Author(s)
  濱田哲暢
- Organizer
  薬物動態学会ワークショップ
- Place of Presentation
  東京大学(東京)(招待講演)
- Year and Date
  2011-05-12
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] 副作用とトランスポータ親和性を指標とし抗がん剤個別化治療戦略2011
- Author(s)
  濱田哲暢
- Organizer
  第25回薬物動態学会ワークショップ
- Place of Presentation
  東京(東京大学)
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] 新規経口分子標的薬抗がん剤の体内動態とPharmacogenomics2011
- Author(s)
  濱田哲暢
- Organizer
  日本臨床腫瘍学会
- Place of Presentation
  パシフィコ横浜(横浜)(招待講演)
- Year and Date
  2011-07-21
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] 上皮成長因子受容体阻害薬(EGFR-TKI)におけるTDM/PGx研究の展望2011
- Author(s)
  濱田哲暢
- Organizer
  日本TDM学会・学術大会
- Place of Presentation
  広島国際会議場(広島)(招待講演)
- Year and Date
  2011-06-01
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] 呼吸器疾患の最前線:基礎から臨床まで抗悪性腫瘍悪の薬効・毒性を薬物動態から考察する2011
- Author(s)
  濱田哲暢
- Organizer
  第65回日本呼吸器学会・日本結核病学会九州支部秋期講演会
- Place of Presentation
  崇城大学ホール(熊本)
- Year and Date
  2011-11-12
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] Metabolic profiles as the predictive biomarkers of erlotinib-induced adverse effects in non-small cell lung cancer (NSCLC) patients2011
- Author(s)
  Hamada A
- Organizer
  American Society of Clinical Oncology
- Place of Presentation
  マコーミックプレス(シカゴ)、米国
- Year and Date
  2011-06-01
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] 上皮成長因子受容体阻害薬(EGFR-TKI)におけるTDM/PGx研究の展望2011
- Author(s)
  濱田哲暢
- Organizer
  第28回日本TDM学会・学術大会
- Place of Presentation
  広島(広島国際会議場)
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] 新規経口分子標的薬抗がん剤の体内動態とPharmacogenomics2011
- Author(s)
  濱田哲暢
- Organizer
  第9回日本臨床腫瘍学会
- Place of Presentation
  横浜(パシフィコ横浜)
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] 良きがん化学療法をめざして分子標的薬におけるPK/PD解析2010
- Author(s)
  濱田哲暢
- Organizer
  九州山口薬学会ファーマシューティカルケア研修会
- Place of Presentation
  別府(ビーコンプラザ)
- Year and Date
  2010-02-13
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] Personalized medicine for non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib2010
- Author(s)
  Akinobu Hamada
- Organizer
  American Association for Cancer Research
- Place of Presentation
  Washington DC, USA
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] 呼吸器疾患の最前線:基礎から臨床まで抗悪性腫瘍悪の薬効・毒性を薬物動態から考察する2010
- Author(s)
  濱田哲暢
- Organizer
  第65回日本呼吸器学会・日本結核病学会九州支部秋期講演会
- Place of Presentation
  熊本(熊本市民会館)
- Year and Date
  2010-11-12
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] Association of pharmacokinetics and germline mutations in EGFR and ABC transporters with erlotinib toxicity in patients with non-small cell lung cancer(NSCLC)2009
- Author(s)
  Akinobu Hamada
- Organizer
  2009Annual meeting American Society of Clinical Oncology
- Place of Presentation
  Orlando, USA
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] 非小細胞肺癌に対する上皮増殖因子受容体チロシンキナーゼ阻害薬の有害事象と薬物動態との相関解析に基づく個別投与設計の開発2009
- Author(s)
  濱田哲暢
- Organizer
  日本臨床薬理学会年会
- Place of Presentation
  パシフィコ横浜(横浜)
- Year and Date
  2009-12-05
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] Pharmacokinetics and Pharmacodynamics, PK/PD of anticancer drugs for personalized medicine2009
- Author(s)
  濱田哲暢
- Organizer
  International Symposium 2009 "New Perspectives in Cancer Rsearch"
- Place of Presentation
  蔚山大(Ulsan, Korea)
- Year and Date
  2009-11-14
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] Pharmacokinetics and Pharmacodynamics, PK/PD of anticancer drugs for personalized medicine2009
- Author(s)
  Akinobu Hamada
- Organizer
  International Symposium2009 "New Perspectives in Cancer Research"
- Place of Presentation
  Ulsan, Korea
- Year and Date
  2009-11-14
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] 日本人におけるカルボプラチンの臨床薬理学的検討とカルバートの式の妥当性2009
- Author(s)
  下方智也、安田宜成、河田健司、濱田哲暢、齋藤秀之、松尾清一、近藤征史、今泉和良、長谷川好規、安藤雄一
- Organizer
  第7回日本臨床腫瘍学会学術集会
- Place of Presentation
  名古屋
- Data Source
  KAKENHI-PROJECT-19590149
[Presentation] 非小細胞肺癌患者におけるエルロチニブの薬物動態変動ならびに毒性との相関解析試験2009
- Author(s)
  佐々木治一郎、濱田哲暢、岩本範博、稲葉恵、岸裕人、浦田真紀、牛島淳、佐伯祥、山下明寿、千場博、齋藤秀之、興梠博次
- Organizer
  第7回日本臨床腫瘍学会学術集会
- Place of Presentation
  名古屋
- Data Source
  KAKENHI-PROJECT-19590149
[Presentation] PK/PD解析から見た抗がん剤の効果・副作用-分子標的薬の至適投与設計法の開発2009
- Author(s)
  濱田哲暢
- Organizer
  医療薬学フォーラム2009
- Place of Presentation
  京都.(京都国際会館)
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] 慢性骨髄性白血病治療薬イマチニブの血中濃度と至適投与量の関連2009
- Author(s)
  濱田哲暢, 川口辰哉, 平山知恵, 中島麗子, 南部健, 山川裕司, 堀川健太郎, 齋藤秀之
- Organizer
  第7回日本臨床腫瘍学会学術集会
- Place of Presentation
  名古屋
- Data Source
  KAKENHI-PROJECT-19590149
[Presentation] 慢性骨髄性白血病治療薬イマチニブの血中濃度と至適投与量の関連2009
- Author(s)
  濱田哲暢
- Organizer
  日本臨床腫瘍学会
- Place of Presentation
  名古屋
- Year and Date
  2009-03-21
- Data Source
  KAKENHI-PROJECT-19590149
[Presentation] 抗悪性腫瘍薬開発における臨床薬理研究の役割非小細胞肺癌に対する上皮増殖因子受容体チロシンキナーゼ阻害薬の有害事象と薬物動態との相関解析に基づく個別投与設計の開発2009
- Author(s)
  濱田哲暢
- Organizer
  第30回日本臨床薬理学会年会
- Place of Presentation
  横浜(パシフィコ横浜)
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] Association of pharmacokinetics and germ-line mutations in EGFR and ABC transporters with erlotinib toxicity in patients with non-small cell lung cancer (NSCLC)2009
- Author(s)
  濱田哲暢
- Organizer
  American Society of Clinical Oncology 2009 Annual Meeting
- Place of Presentation
  Orange county convention center(Orlando, USA)
- Year and Date
  2009-05-31
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] PK/PD解析から見た抗がん剤の効果・副作用分子標的薬の至適投与設計法の開発2009
- Author(s)
  濱田哲暢
- Organizer
  医療薬学フォーラム
- Place of Presentation
  京都国際会館(京都)
- Year and Date
  2009-12-12
- Data Source
  KAKENHI-PROJECT-21590167
[Presentation] Therapeutic efficacy of imatinib at a reduced dose to relieve adverse effects was equivalent to the standard dose in chronic myeloid leukemia patients2008
- Author(s)
  Hamada A, Kawaguchi T, Nakajima R, Hirayama C, Nanbu T, Watanabe H, Saito H
- Organizer
  American Association for Cancer Research 99th Annual Meeting
- Place of Presentation
  San Diego, USA
- Data Source
  KAKENHI-PROJECT-19590149
[Presentation] K562細胞におけるBCR-ABL非依存的活性化ERKのimatinib抵抗性獲得への寄与2008
- Author(s)
  南部健, 中川亜衣子, 川口辰哉, 荒木令江, 濱田哲暢, 齋藤秀之
- Organizer
  第2回次世代を担う若手医療薬科学シンポジウム
- Place of Presentation
  京都
- Data Source
  KAKENHI-PROJECT-19590149
[Presentation] イマチニブ治療中の慢性骨髄性白血病患者における細胞内および血中薬物濃度の相関解析2008
- Author(s)
  中島麗子, 南部健, 平山知絵, 濱田哲暢, 川口辰哉, 齋藤秀之
- Organizer
  第29回日本臨床薬理学会年会
- Place of Presentation
  東京
- Data Source
  KAKENHI-PROJECT-19590149
[Presentation]2008
- Author(s)
  山川裕司, 中島麗子, 平山知絵, 濱田哲暢, 川口辰哉, 満屋裕明, 齋藤秀之
- Organizer
  日本人における慢性骨髄性白血病治療薬イマチニブ(IM)の母集団薬物動態解析
- Place of Presentation
  東京
- Data Source
  KAKENHI-PROJECT-19590149
[Presentation] Therapeutic efficacy of imatinib at a reduced dose to relieve adverse effects were equivalent to the standard dose in chronic myeloid leukemia patients.2008
- Author(s)
  Akinobu Hamada
- Organizer
  米国癌学会
- Place of Presentation
  San Diego, USA
- Year and Date
  2008-04-16
- Data Source
  KAKENHI-PROJECT-19590149
[Presentation] Characteristics of chronic-phase CML patients having durable cytogenetic response to low-dose imatinib2008
- Author(s)
  Kawaguchi T, Hamada A, Nakashima R, Horikawa K, Ishihara S, Saito H, Hiroaki Mitsuya
- Organizer
  American Society of Hematology 50th Annual Meeting
- Place of Presentation
  San Francisco, USA
- Data Source
  KAKENHI-PROJECT-19590149
[Presentation] S-1投与によるラット肝breast cancer resistance protein (Bcrp)の発現亢進と塩酸イリノテカン(CPT-11)体内動態変動2007
- Author(s)
  横尾浩司, 濱田哲暢, 渡邊博志, 今井智之, 藤本裕美, 佐々木裕, 齋藤秀之
- Organizer
  第29回生体膜と薬物の相互作用シンポジウム
- Place of Presentation
  仙台
- Data Source
  KAKENHI-PROJECT-19590149
[Presentation] 塩酸アムルビシンと塩酸イリノテカン併用における薬物動態学的検討2007
- Author(s)
  前田友紀子, 實松絵美子, 濱田哲暢, 齋藤秀之
- Organizer
  第28回日本臨床薬理学会年会
- Place of Presentation
  宇都宮
- Data Source
  KAKENHI-PROJECT-19590149
[Presentation] イマチニブ(IM)抵抗性白血病細胞株K562-IMにおけるABCトランスポータ及び有機カチオントランスポータの発現・機能解析に基づくIM耐性獲得機序の解明2007
- Author(s)
  南部健, 平山知絵, 渡邊博志, 中島麗子, 濱田哲暢, 國安明彦, 中山仁, 川口辰哉, 齋藤秀之
- Organizer
  第29回生体膜と薬物の相互作用シンポジウム
- Place of Presentation
  仙台
- Data Source
  KAKENHI-PROJECT-19590149

1. SAITO Hideyuki (40225727)

# of Collaborated Projects: 6 results

# of Collaborated Products: 0 results
2. KAWAGUCHI Tatsuya (50244116)

# of Collaborated Projects: 4 results

# of Collaborated Products: 14 results
3. SASAKI Ji-ichiro (60419637)

# of Collaborated Projects: 3 results

# of Collaborated Products: 6 results
4. NONOGUCHI Hiroshi (30218341)

# of Collaborated Projects: 3 results

# of Collaborated Products: 2 results
5. MATSUMOTO Mitsuhiro (70253755)

# of Collaborated Projects: 2 results

# of Collaborated Products: 0 results
6. MASUDA Satohiro (90303825)

# of Collaborated Projects: 2 results

# of Collaborated Products: 0 results
7. WATANABE Hiroshi (70398220)

# of Collaborated Projects: 1 results

# of Collaborated Products: 4 results
8. ANDO Yuichi (10360083)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
9. TAMURA Kenji (60340783)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
10. FUJIWARA Yutaka (70464261)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
11. FUKATSU Atsushi (90247685)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
12. KONDO Keiichi (20332827)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
13. TANIGAWARA Yusuke (30179832)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
14. NAKAJIMA Masamitsu (20198097)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
15. 小林進 (70792836)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
16. 田中広祐 (50894119)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
17. 柳下薫寛 (80781674)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
18. 斎藤秀之

# of Collaborated Projects: 0 results

# of Collaborated Products: 46 results

Hamada Akinobu 濱田 哲暢

濱田 哲暢 ハマダ アキノブ

HAMADA Akinobu 濱田 哲暢

Research Projects

Research Products

Co-Researchers

Development of a novel cell differentiation cancer therapy

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Personalized cancer chemotherapy: efficacy and safety based on pharmacokinetics and pharmacogeneticsPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Novel strategy for development of suppressive drugs for kidney disease based on inhibition of metabolic production of uremic toxins

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of personalized medicine for cancer chemotherapy according to a variety of sensitivity and pharmacokineticsPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of an individualized therapy for establishing the optimal dosage by analysis of pharmacological genePrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Strategy for protection of kidney injury based on functioal relation betwee renal specific stress response mechanisms and xenobiotic detoxication systems

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Molecular Biological Studies on Relationships between Changes in Renal Tubular Transporter Gene Expressions and Deterioration of Drug Excretory Functions in Renal Diseases

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

The prediction of adverse effect and determination of the maximum tolerated dose in chemotherapy of lung cancer based on clinical and molecular pharmacology

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small cell lung cancer2012

Author(s)

Journal Title

Data Source

[Journal Article] Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient2012

Author(s)

Journal Title

Data Source

[Journal Article] Effects of genetic variants in SLC22A2 organic cation transporter2and SLC47A1 multidrug and toxin extrusion1transporter on cisplatin-induced adverse events2012

Author(s)

Journal Title

Data Source

[Journal Article] Effects of Genetic Variants in SLC22A2 Organic Cation Transporter 2 and SLC47A1 Multidrug and Toxin Extrusion 1 Transporter on Cisplatin-induced Adverse Events2012

Author(s)

Journal Title

NAID

Data Source

[Journal Article] Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis2012

Author(s)

Journal Title

NAID

Data Source

[Journal Article] Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small cell lung cancer2012

Author(s)

Journal Title

Data Source

Hamada Akinobu 濱田哲暢

濱田哲暢ハマダアキノブ

HAMADA Akinobu 濱田哲暢